任润玲, 闫志风, 李明霞, 王铭洋, 王楠, 吴迪, 孟元光. 特殊病理类型子宫内膜癌分子分型特征及其临床应用的研究进展[J]. 解放军医学院学报, 2023, 44(3): 287-292. DOI: 10.3969/j.issn.2095-5227.2023.03.014
引用本文: 任润玲, 闫志风, 李明霞, 王铭洋, 王楠, 吴迪, 孟元光. 特殊病理类型子宫内膜癌分子分型特征及其临床应用的研究进展[J]. 解放军医学院学报, 2023, 44(3): 287-292. DOI: 10.3969/j.issn.2095-5227.2023.03.014
REN Runling, YAN Zhifeng, LI Mingxia, WANG Mingyang, WANG Nan, WU Di, MENG Yuanguang. Research advances in molecular subtyping and clinical application of special pathological type endometrial carcinoma[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2023, 44(3): 287-292. DOI: 10.3969/j.issn.2095-5227.2023.03.014
Citation: REN Runling, YAN Zhifeng, LI Mingxia, WANG Mingyang, WANG Nan, WU Di, MENG Yuanguang. Research advances in molecular subtyping and clinical application of special pathological type endometrial carcinoma[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2023, 44(3): 287-292. DOI: 10.3969/j.issn.2095-5227.2023.03.014

特殊病理类型子宫内膜癌分子分型特征及其临床应用的研究进展

Research advances in molecular subtyping and clinical application of special pathological type endometrial carcinoma

  • 摘要: 特殊病理类型子宫内膜癌(special type endometrial carcinoma,STEC)是一类病死率较高的妇科恶性肿瘤,相较常见的子宫内膜样腺癌,STEC进展快、复发率高,且具有显著组织异型性,传统病理分型无法满足临床需要。近年来提出的TCGA等分子分型对STEC的诊治具有重要意义,本文就分子分型在浆液性癌、透明细胞癌、癌肉瘤、去/未分化癌和高级别不明确子宫内膜癌五类STEC中的研究进展进行综述,包括分子分型在STEC诊断和鉴别、靶向药物研发、疗效预测及预后中的应用,以期为临床合理应用分子分型提供参考。

     

    Abstract: Special pathological type endometrial carcinoma (STEC) is a kind of serious gynecological tumor. Compared with common endometrioid adenocarcinoma, STEC has a rapid progress, a high recurrence rate, and a large histological heterogeneity. The traditional pathological classification cannot meet the clinical needs. In recent years, molecular subtyping such as TCGA classification is of great significance for the diagnosis and treatment of STEC. This article reviews the research progress of molecular subtyping in five categories of STEC: serous carcinoma, clear cell carcinoma, carcinosarcoma, dedifferentiated/ undifferentiated carcinoma, and high-grade uncertain endometrial carcinoma, including the application of molecular subtyping in the diagnosis and differentiation of STEC, research and development of targeted drugs, efficacy prediction, and prognosis, with a view to providing reference for the rational clinical application of molecular subtyping.

     

/

返回文章
返回